Posted On: Monday, November 16, 2020
NeuroLux has launched the first commercially manufactured Optofluidics device, providing simultaneous drug delivery and optogenetics. It is an implantable, lightweight, battery-free device with parameter control on the individual device level. The device combines soft microfluidic and microscale inorganic light-emitting diode probes for programmable pharmacological and optogenetics, designed to offer the features of drug refillability and adjustable flow rate, together with programmable control over the temporal profiles.
The device is available at different probe lengths of 2, 4, and 6mm with a drug reservoir volume of 0.5 µL.
This break-through device, combine drug delivery and optogenetics into one platform. The bio-compatible and refillable drug reservoir can be used to deliver drugs or viruses through a microfluidic channel in a controllable release. The device can target organs such as the brain, spinal cord, and peripheral nerves. We hope that these new capabilities will help neuroscientists and pharmacologists further their research discoveries.
For more information, please click here to go to the product launch page. Potential Beta Testers can register here starting November 15th, 2020. Please contact firstname.lastname@example.org for further inquiries.